Development of an in vitro assay for the screening of substances capable of dissolving calcium oxalate crystals.
Despite the risk of kidney damage, lithotripsy is the usual way of treating calcium oxalate (CaOx) stones, the most common type of nephrolithiasis, because no effective chemolytic agents are available. However, the search of new calcium chelators, less toxic than the current ones, continues, and some of them could be tested in experimental models of nephrolithiasis, after their ability of dissolving CaOx crystals is verified. In this connection, we developed a simple assay that requires only inexpensive equipment available in most laboratories for the screening of substances potentially capable of dissolving CaOx crystals. In particular, we decided to investigate whether substances previously shown to inhibit CaOx precipitation were also capable of dissolving this salt. Briefly, CaOx tablets of highly reproducible weight (4.55 +/- 0.07 mg) were prepared by spinning, at high speed (16,000 g), microcentrifuge tubes in which 500 microl aliquots of 0.1 M sodium oxalate and 0.1 M calcium chloride at pH 6 were added. When these tablets were incubated overnight with solutions at different concentrations of EDTA, sodium citrate, manganese chloride, sodium sulfate, sodium chloride, malic acid, succinic acid and gluconic acid, a significant dissolving activity was observed for EDTA ( approximately 25% at 0.25 M), sodium citrate ( approximately 30% at 1 M) and manganese chloride ( approximately 20% at 0.5 M). A good linear correlation (r2 = 0.84, p < 0.05) was found between the affinity for calcium and the activity of EDTA, sodium citrate, sodium sulfate, malic acid, succinic acid and gluconic acid, indicating that these compounds act mainly by chelating the calcium ion. Instead, manganese was supposed to act by interacting with the oxalate ion.
Saso
L
L
Institute of Pharmacology and Pharmacognosy, University of Rome 'La Sapienza', Rome, Italy.
Valentini
G
G
Leone
M G
MG
Grippa
E
E
Silvestrini
B
B
D002129:Calcium Oxalate / Q000737:chemistry*; D002614:Chelating Agents / Q000737:chemistry*; D002712:Chlorides / Q000737:chemistry*; D002951:Citrates / Q000737:chemistry*; D003460:Crystallization; D004353:Drug Evaluation, Preclinical; D004492:Edetic Acid / Q000737:chemistry*; D066298:In Vitro Techniques; D007202:Indicators and Reagents / Q000737:chemistry; D007669:Kidney Calculi / Q000737:chemistry*; D017895:Manganese Compounds / Q000737:chemistry*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D012965:Sodium Chloride; D000077559:Sodium Citrate; D012995:Solubility
D002614:Chelating Agents; D002712:Chlorides; D002951:Citrates; D007202:Indicators and Reagents; D017895:Manganese Compounds; D000077559:Sodium Citrate; D002129:Calcium Oxalate; D012965:Sodium Chloride; D004492:Edetic Acid; C025340:manganese chloride